was successfully added to your cart.

Carrinho

MedAlliance

Por 4 de março de 2021

MedAlliance

Por 4 de março de 2021

MedAlliance Receives Fourth FDA Breakthrough Device Designation for Sirolimus Drug-Eluting Balloon in Treatment of De Novo Coronary Lesions

MedAlliance Receives Fourth FDA Breakthrough Device Designation for Sirolimus Drug-Eluting Balloon in Treatment of De Novo Coronary Lesions

Author PR Newswire

More posts by PR Newswire